Improved Growth and Anemia in HIV-Infected African Children Taking Cotrimoxazole Prophylaxis


    loading  Checking for direct PDF access through Ovid

Abstract

The impact of cotrimoxazole (CTX) on growth and/or anemia was investigated in 541 human immunodeficiency virus-infected, antiretroviral therapy–naive Zambian children enrolled in the Children with HIV Antibiotic Prophylaxis trial. Compared with children randomized to receive placebo, children randomized to receive CTX had slower decreases in weight-for-age (P  =  .04) and height-for-age (P  =  .01), and greater increase in hemoglobin level (P  =  .01). These findings argue for expanded early CTX use.

    loading  Loading Related Articles